Central Public Health Laboratory, Kampala, Uganda.
Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
PLoS One. 2022 Jun 30;17(6):e0268127. doi: 10.1371/journal.pone.0268127. eCollection 2022.
Over the past several years, only approximately 50% of HIV-exposed infants received an early infant diagnosis test within the first two months of life. While high attrition and mortality account for some of the shortcomings in identifying HIV-infected infants early and putting them on life-saving treatment, fragmented and challenging laboratory systems are an added barrier. We sought to determine the accuracy of using HIV viral load assays for infant diagnosis of HIV.
We enrolled 866 Ugandan infants between March-April 2018 for this study after initial laboratory diagnosis. The median age was seven months, while 33% of infants were less than three months of age. Study testing was done using either the Roche or Abbott molecular technologies at the Central Public Health Laboratory. Dried blood spot samples were prepared according to manufacturer-recommended protocols for both the qualitative and quantitative assays. Viral load test samples for the Roche assay were processed using two different buffers: phosphate-buffered saline (PBS: free virus elution viral load protocol [FVE]) and Sample Pre-Extraction Reagent (SPEX: qualitative buffer). Dried blood spot samples were processed for both assays on the Abbott using the manufacturer's standard infant diagnosis protocol. All infants received a qualitative test for clinical management and additional paired quantitative tests.
858 infants were included in the analysis, of which 50% were female. Over 75% of mothers received antiretroviral therapy, while approximately 65% of infants received infant prophylaxis. The Roche SPEX and Abbott technologies had high sensitivity (>95%) and specificity (>98%). The Roche FVE had lower sensitivity (85%) and viral load values.
To simplify and streamline laboratory practices, HIV viral load may be used to diagnose HIV infection in infants, particularly using the Roche SPEX and Abbott technologies.
在过去的几年中,只有大约 50%的 HIV 暴露婴儿在生命的头两个月内接受了早期婴儿诊断检测。虽然高淘汰率和死亡率是早期发现和让 HIV 感染婴儿接受挽救生命的治疗的一些不足之处,但分散和具有挑战性的实验室系统是一个额外的障碍。我们试图确定使用 HIV 病毒载量检测来诊断婴儿 HIV 感染的准确性。
我们在 2018 年 3 月至 4 月期间招募了 866 名乌干达婴儿进行这项研究,这些婴儿在最初的实验室诊断后参与了这项研究。中位数年龄为 7 个月,而 33%的婴儿不到 3 个月。研究检测使用罗氏或雅培分子技术在中央公共卫生实验室进行。根据制造商推荐的方案,制备了用于定性和定量检测的干血斑样本。罗氏检测的病毒载量检测样本使用两种不同的缓冲液进行处理:磷酸盐缓冲盐水(PBS:游离病毒洗脱病毒载量方案[FVE])和样品预提取试剂(SPEX:定性缓冲液)。雅培使用制造商的标准婴儿诊断方案对所有干血斑样本进行了两种检测。所有婴儿都接受了定性检测以进行临床管理,并进行了额外的配对定量检测。
858 名婴儿被纳入分析,其中 50%为女性。超过 75%的母亲接受了抗逆转录病毒治疗,而大约 65%的婴儿接受了婴儿预防治疗。罗氏 SPEX 和雅培技术具有高灵敏度(>95%)和特异性(>98%)。罗氏 FVE 的灵敏度较低(85%),病毒载量值较低。
为了简化和简化实验室实践,HIV 病毒载量可用于诊断婴儿的 HIV 感染,特别是使用罗氏 SPEX 和雅培技术。